EUVIMEDObjevte EUVIMED
Übersichtsarbeit

A review of proton pump inhibitor use in cystic fibrosis and considerations for deprescribing

Nicole E Omecene iD, Nicole Wilcox, Alexandra L Cox, Pearl Ham, Ryan Ong, Andrew T Barber, Kristin M Zimmerman

Pediatric Pulmonology · 2024

DOI: 10.1002/ppul.27229 ↗

At a glance

Übersichtsarbeit in Pediatric Pulmonology, 2024. Written by Nicole E Omecene and 6 co-authors. Institution: Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA. Major MEDLINE topics: Cystic Fibrosis, Proton Pump Inhibitors, Deprescriptions, Gastroesophageal Reflux. Cited 2 times so far (Crossref); 88 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Use of proton‐pump inhibitors (PPIs) is common among people with cystic fibrosis (pwCF) both for the management of suspected GERD, as well as pancreatic enzyme replacement therapy augmentation. Despite their use, limited data exist to demonstrate a clinically significant impact of PPIs on key endpoints in pwCF. Furthermore, the advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy may modify the need for use. These notions, coupled with the potential for adverse outcomes associated with long‐term PPI use in pwCF, should facilitate re‐evaluation of long‐term PPI use in pwCF and promote potential deprescribing. Despite limited data on PPI deprescribing in pwCF, it intuitively mirrors the existing guidance in adults in the general population, but with added consideration given to tapering strategy, and monitoring for CF‐specific outcomes such as nutritional and respiratory status. The development of a monitoring and re‐initiation plan is key to reducing deprescribing inertia. This review aims to summarize the evidence that details the concern for long‐term use of PPIs and provide CF clinicians with rationale and guidance on how to approach deprescribing in their practice.

Subjects

MeSH terms (MEDLINE)

Cystic FibrosisProton Pump InhibitorsDeprescriptionsGastroesophageal RefluxHumans

Author keywords

adverse drug reactionexocrine pancreatic insufficiencygastroesophageal refluxpolypharmacy

Substances

Proton Pump Inhibitors

Authors and institutions

  • Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA.
  • Department of Pharmacy, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia, USA.
  • Department of Pharmacy, Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, USA.
  • Division of Pediatric Pulmonary and Sleep Medicine, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia, USA.

ORCID profiles: Nicole E Omecene

Cite

APA

Omecene, N. E., Wilcox, N., Cox, A. L., Ham, P., Ong, R., Barber, A. T., & Zimmerman, K. M. (2024). A review of proton pump inhibitor use in cystic fibrosis and considerations for deprescribing. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27229

Vancouver

Omecene NE, Wilcox N, Cox AL, Ham P, Ong R, Barber AT, et al. A review of proton pump inhibitor use in cystic fibrosis and considerations for deprescribing. Pediatric Pulmonology. 2024. doi:10.1002/ppul.27229

BibTeX
@article{Omecene2024,
  author = {Omecene, Nicole E and Wilcox, Nicole and Cox, Alexandra L and Ham, Pearl and Ong, Ryan and Barber, Andrew T and Zimmerman, Kristin M},
  title = {A review of proton pump inhibitor use in cystic fibrosis and considerations for deprescribing},
  journal = {Pediatric Pulmonology},
  year = {2024},
  doi = {10.1002/ppul.27229}
}
Start for free →